Characterization of [11C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain
Creators
- 1. Karolinska Institutet, Karolinska University Hospital, Department of Clinical Neuroscience, Center for Psychiatric Research, Stockholm (Sweden)
- 2. H. Lundbeck A/S, Synaptic Transmission, Valby (Denmark)
- 3. H. Lundbeck A/S, Discovery Chemistry and DMPK, Valby (Denmark)
- 4. Pfizer Inc., Neuroscience and Pain Research Unit, Cambridge, MA (United States)
- 5. AstraZeneca PET Science Center at Karolinska Institutet, Personalized Health Care and Biomarkers, Stockholm (Sweden)
- 6. Yale University, Department of Radiology and Biomedical Imaging, New Haven, CT (United States)
Description
[11C]Lu AE92686 is a positron emission tomography (PET) radioligand that has recently been validated for examining phosphodiesterase 10A (PDE10A) in the human striatum. [11C]Lu AE92686 has high affinity for PDE10A (IC50 = 0.39 nM) and may also be suitable for examination of the substantia nigra, a region with low density of PDE10A. Here, we report characterization of regional [11C]Lu AE92686 binding to PDE10A in the nonhuman primate (NHP) brain. A total of 11 PET measurements, seven baseline and four following pretreatment with unlabeled Lu AE92686 or the structurally unrelated PDE10A inhibitor MP-10, were performed in five NHPs using a high resolution research tomograph (HRRT). [11C]Lu AE92686 binding was quantified using a radiometabolite-corrected arterial input function and compartmental and graphical modeling approaches. Regional time-activity curves were best described with the two-tissue compartment model (2TCM). However, the distribution volume (VT) values for all regions were obtained by the Logan plot analysis, as reliable cerebellar VT values could not be derived by the 2TCM. For cerebellum, a proposed reference region, VT values increased by ∝30 % with increasing PET measurement duration from 63 to 123 min, while VT values in target regions remained stable. Both pretreatment drugs significantly decreased [11C]Lu AE92686 binding in target regions, while no significant effect on cerebellum was observed. Binding potential (BPND) values, derived with the simplified reference tissue model (SRTM), were 13-17 in putamen and 3-5 in substantia nigra and correlated well to values from the Logan plot analysis. The method proposed for quantification of [11C]Lu AE92686 binding in applied studies in NHP is based on 63 min PET data and SRTM with cerebellum as a reference region. The study supports that [11C]Lu AE92686 can be used for PET examinations of PDE10A binding also in substantia nigra. (orig.)
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00259-016-3544-9Additional details
Identifiers
Publishing Information
- Journal Title
- European Journal of Nuclear Medicine and Molecular Imaging
- Journal Volume
- 44
- Journal Issue
- 2
- Journal Page Range
- p. 308-320
- ISSN
- 1619-7070
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 48030200
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BLOOD; BRAIN; CARBON 11; CATABOLISM; COMPUTERIZED TOMOGRAPHY; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; LIGANDS; MASS SPECTROSCOPY; METABOLITES; MONKEYS; PHOSPHODIESTERASES; POSITRON COMPUTED TOMOGRAPHY; RADIOCHEMISTRY; RADIOPHARMACEUTICALS; TIME DEPENDENCE; UPTAKE
- Descriptors DEC
- ANIMALS; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BIOLOGICAL MATERIALS; BODY; BODY FLUIDS; CARBON ISOTOPES; CENTRAL NERVOUS SYSTEM; CHEMISTRY; CHROMATOGRAPHY; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; ENZYMES; ESTERASES; EVEN-ODD NUCLEI; HYDROLASES; ISOTOPES; LABELLED COMPOUNDS; LIGHT NUCLEI; LIQUID COLUMN CHROMATOGRAPHY; MAMMALS; MATERIALS; METABOLISM; MINUTES LIVING RADIOISOTOPES; NERVOUS SYSTEM; NUCLEI; ORGANIC COMPOUNDS; ORGANS; PRIMATES; PROTEINS; RADIOACTIVE MATERIALS; RADIOISOTOPES; SEPARATION PROCESSES; SPECTROSCOPY; TOMOGRAPHY; VERTEBRATES